HeartBeam Receives FDA Clearance
DENVER, Colo., Dec 16, 2024 (247marketnews.com)- HeartBeam (NASDAQ: BEAT) stated that the US Food and Drug Administration (FDA) granted the HeartBeam system 510(k) clearance for comprehensive arrhythmia assessment and the Company will initiate an Early Access Program to gain vital patient and physician feedback, in preparation for commercial launch.
The HeartBeam device is a high-fidelity electrocardiogram (ECG) system that captures heart signals from three distinct directions for actionable heart health information and is the first-of-its-kind to receive FDA clearance.
Robert Eno, HeartBeam’s CEO, commented, “It’s well documented that patients who delay seeking care for their cardiac symptoms face worse clinical outcomes. The ability for patients to capture high-fidelity ECG signals from three directions wherever they are when symptoms occur will help patients get the care they need in a timelier manner. The FDA clearance of our technology is a significant milestone for the Company that brings us one step closer to fulfilling our vision of providing unprecedented cardiac insights to individuals and physicians.”
To view HeartBeam System video
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (BEAT)
- HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth
- HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
- HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation
- HeartBeam Reports Fourth Quarter and Full Year 2024 Results
- HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025